DOCSLIB.ORG

B‑Cell Activating Factor Receptor Expression Is Associated with Germinal Center B‑Cell Maintenance

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
B‑Cell Activating Factor Receptor Expression Is Associated with Germinal Center B‑Cell Maintenance EXPERIMENTAL AND THERAPEUTIC MEDICINE 17: 2053-2060, 2019 B‑cell activating factor receptor expression is associated with germinal center B‑cell maintenance FRANCISCO JOSUÉ CARRILLO-BALLESTEROS1, EDITH OREGON-ROMERO1, RAMON ANTONIO FRANCO-TOPETE2, LUIS HUMBERTO GOVEA-CAMACHO3, ALVARO CRUZ1, JOSÉ FRANCISCO MUÑOZ-VALLE1, FELIPE JESÚS BUSTOS-RODRÍGUEZ2, ANA LAURA PEREIRA-SUÁREZ4 and CLAUDIA AZUCENA PALAFOX-SÁNCHEZ1 1Research Institute of Biomedical Sciences, Department of Medical Clinics; 2Department of Microbiology and Pathology, University Center for Health Sciences, University of Guadalajara; 3Department of Otorhinolaryngology, West National Medical Center, Mexican Institute of Social Security; 4Department of Physiology, University Center for Health Sciences, University of Guadalajara, Guadalajara, Jalisco 44340, México Received April 26, 2018; Accepted November 23, 2018 DOI: 10.3892/etm.2019.7172 Abstract. B-cell activating factor (BAFF) is a major cytokine was observed inside the follicle, mainly in the dark zone. that regulates B-cell survival, maturation and differentia- The present results indicate that BAFF is implicated in the tion through its binding with its receptors: BAFF receptor maintenance of GCs. BAFF-R overexpression in the MZ, (BAFF-R), transmembrane activator and cyclophilin ligand co-localizated with BAFF, suggests that these proteins consti- interactor (TACI) and B-cell maturation antigen (BCMA). tute the principal pathway for the maintenance of the naïve These receptors have been demonstrated to be involved in B-cell population. Furthermore, TACI and BCMA have a role tertiary lymphoid structure formation; however, their role in the GC, where processes of B-cell selection, proliferation in germinal centers (GCs) has remained elusive. The aim of and differentiation into immunoglobulin-secreting plasma the present study was to determine the expression profiles cells occur. of BAFF and its receptors in secondary lymphoid tissues. Tonsils resected due to chronic tonsillitis were used as Introduction lymphoid tissues. To confirm the presence of GCs identified based on their typical structure, CD21 antibody staining was B-cell activating factor (BAFF), also known as B-lymphocyte employed. The expression of BAFF, BAFF-R, TACI and stimulator, is a cytokine belonging to the tumor necrosis factor BCMA was assessed by immunohistochemistry. BAFF was ligand superfamily, existing either as a type 2 transmembrane highly expressed in all regions of the follicle, but the highest protein or in its soluble form (1). BAFF and its homolog A BAFF expression was detected in the mantle zone (MZ). A PRoliferation-Inducing Ligand (APRIL) have an important high expression of BAFF-R was observed on lymphocytes in role in B-cell maturation, survival, selection and differen- the MZ in comparison with the other regions (~80%; P<0.05), tiation (2). The major sources for BAFF cytokine are several which was co-localizated with BAFF (r=0.646; P<0.001), in innate immune cell types, including monocytes, macro- the MZ. TACI and BCMA exhibited similar expression among phages (3), neutrophils (4) and dendritic cells in response the different zones of the GCs, and co-localization with BAFF to Toll-like receptors, type I and II interferons (IFNs) (5), interleukin-10 (6) and granulocyte colony-stimulating factor expression (7). Furthermore, fibroblast-like cells (8) and astrocytes (9) are also able to produce BAFF, and so are B cells (10) and T cells (11) in secondary lymphoid tissues, Correspondence to: Dr Claudia Azucena Palafox-Sánchez, including the spleen, lymph nodes and tonsils. Increased Research Institute of Biomedical Sciences, Department of levels of BAFF have been associated with autoimmune Medical Clinics, University Center for Health Sciences, University diseases (12), including systemic lupus erythematosus (13), of Guadalajara, 950 Sierra Mojada, Edificio Q, Guadalajara, Jalisco 44340, México Sjögren's syndrome (14) and rheumatoid arthritis (15), as well E-mail: [email protected] as with multiple myeloma (16), non-Hodgkin's lymphoma (17), B-lineage lymphomas (18) and Hodgkin's lymphoma (19). Key words: B-cell activating factor, B-cell activating factor A total of 3 BAFF-binding receptors have been estab- receptor, transmembrane activator and cyclophilin ligand interactor, lished, namely BAFF receptor (BAFF‑R), which is specific B-cell maturation antigen, expression, germinal centers for BAFF, and two others that are shared with the homo- logue APRIL, transmembrane activator and cyclophilin ligand interactor (TACI) and B-cell maturation antigen 2054 CARRILLO-BALLESTEROS et al: BAFF AND BAFF RECEPTOR EXPRESSION IN GERMINAL CENTERS (BCMA) (2). BAFF-R is essential for B-cell maturation at zone (MZ), consisting of a lymphocyte fringe that surrounds early transitional stages, particularly from T1 to T2 B cells, the GC and exhibits an asymmetric distribution regarding the as well as for B-cell survival (20). TACI is important for central axis to the follicle; and the interfollicular zone (IZ) T-cell-independent responses of B cells, immunoglobulin (Ig) as the remaining area excluding the GCs. Finally, the pres- class switch and it is considered to be a negative regulator of ence of GCs was immunohistochemically confirmed by CD21 B-cell homeostasis (21-23). Whereas, BCMA promotes plasma labeling and as described below. cells survival (24). All three BAFF receptors, BAFF-R, TACI and BCMA, are expressed on B cells; TACI is additionally Immunohistochemical staining. Once tissue sections were expressed on activated T cells, while BAFF-R is also expressed re-hydrated, antigen retrieval was accomplished in one step on follicular helper T cells (TFH ) (21,25). with a water steamer at 96 degrees for 30 min, while slides were Germinal centers (GCs) are important structures in submerged in a cup with 10 mM sodium citrate buffer (pH=6) secondary lymphoid tissues where T cell-dependent immune for later staining with rat monoclonal antibody to BAFF (cat. responses occur, and BAFF has been identified to be impli- no. ab16081; dilution, 1:100), rabbit monoclonal antibodies cated in their formation from lymphoid tissues in murine to TACI (cat. no. ab79023; dilution, 1:200) and BCMA (cat. models (26,27), as well as in tertiary lymphoid structures in no. ab5972; dilution, 1:400), or 1 mM EDTA buffer (pH=9) for autoimmune diseases (28,29). A study reported that BAFF and later staining with mouse monoclonal antibodies to CD21 (cat. APRIL are associated with artery tertiary lymphoid organs in no. ab9492; dilution, 1:10) and BAFF-R (cat. no. ab16232; dilu- giant-cell arteritis, and that BAFF is highly expressed within tion, 1:500) from Abcam (Cambridge, UK). After cooling, slides infiltrating, vascular and endothelial cells, suggesting their were treated with a peroxidase blocking solution composed of involvement in ectopic GCs; however, BAFF receptors were 3% hydrogen peroxide and 10% methanol solution for 15 min not analyzed (28). Likewise, in Hodgkin (30) and non-Hodgkin at room temperature. The slides were then blocked with serum lymphoma (31), the BAFF/BAFF-R pathway has an important depending on the secondary antibody source: Horse serum for role and has been proposed as a predictor of lymphoma devel- CD21 and BAFF-R; rabbit serum for BAFF; and goat serum for opment in primary Sjögren's syndrome (32). However, only TACI and BCMA antibodies (VECTASTAIN Elite ABC-HRP few studies have assessed the expression of BAFF receptors Kit; Vector Laboratories, Inc., Burlingame, CA, USA). The in non-neoplastic lymphoid tissues in humans (30,33,34). samples were incubated with the primary antibodies overnight Therefore, the distribution and expression profiles of BAFF at 4˚C. Detection was performed with the respective provided and their receptors, BAFF-R, TACI and BCMA, in secondary secondary biotinylated antibody (1:200), for 30 min at room follicles from tonsil tissues were analyzed in the present study. temperature and streptavidin (VECTASTAIN Elite ABC-HRP Kit; Vector Laboratories, Inc.) using diaminobenzidine (DAB) Materials and methods until a red-brown color developed. Finally, counterstaining was performed using Harris' hematoxylin. Patients. Tonsils were obtained from nine patients submitted Immunohistochemistry slide staining for CD3 and CD20 to a routine tonsillectomy performed at the Department was performed using the automated Ventana Benchmark of Otorhinolaryngology of the Mexican Institute of Social ULTRA (Roche Diagnostics, Basel, Switzerland) following the Security (Guadalajara, Mexico). The mean age of the patients manufacturer's recommended protocols for paraffin‑embedded was 12 years (range, 4-41 years), and the cohort comprised sections. The primary antibodies anti-CD3 (2GV6) rabbit 7 females and 2 males. The clinical diagnosis for the majority of monoclonal antibody (cat. no. 790-4341) and anti-CD20 the patients was chronic tonsillitis and grade III or IV tonsillar (L26) mouse monoclonal antibody [cat. no. 760-2531; Ventana hypertrophy. All of the patients, or their guardians in the case of iVIEW PATHWAY (Roche Diagnostics) were obtained predi- minors, provided written informed consent in accordance with luted by Roche Diagnostics, and were optimized for use on the Declaration of Helsinki and the current national guidelines Ventana staining platforms. Detection was performed with the and regulations. The ethics committee of the University Center iVIEW DAB detection kit (Roche Diagnostics)]. for Health Sciences, University of Guadalajara (Guadalajara,
Load more

Recommended publications
  • CD137 Microbead Kit CD137 Microbead + Cells
    CD137 MicroBead Kit human Order no. 130-093-476 Contents 1.2 Background information 1. Description The activation-induced antigen CD137 (4-1BB) is a 30 kDa glycoprotein of the tumor necrosis factor (TNF) receptor 1.1 Principle of the MACS® Separation + + superfamily. It is mainly expressed on activated CD4 and CD8 1.2 Background information T cells, activated B cells, and natural killer cells, but can also be 1.3 Applications found on resting monocytes and dendritic cells. As a costimulatory molecule, CD137 is involved in the activation 1.4 Reagent and instrument requirements and survival of CD4, CD8, and NK cells. Its engagement enhances 2. Protocol expansion of T cells and activates them to secrete cytokines. CD137 has been described to be a suitable marker for antigen- 2.1 Sample preparation specific activation of human CD8+ T cells, as CD137 is not expressed 2.2 Magnetic labeling on resting CD8+ T cells and its expression is reliably induced after 2.3 Magnetic separation 24 hours of stimulation.¹,² 3. Example of a separation using the CD137 MicroBead Kit 1.3 Applications 4. References ● Enrichment of CD137+ T cells for phenotypical and functional 5. Appendix characterization. ● Enrichment of activated antigen-specific T cells after antigen- Warnings specific stimulation. Reagents contain sodium azide. Under acidic conditions sodium 1.4 Reagent and instrument requirements azide yields hydrazoic acid, which is extremely toxic. Azide ● compounds should be diluted with running water before discarding. Buffer: Prepare a solution containing phosphate-buffered These precautions are recommended to avoid deposits in plumbing saline (PBS), pH 7.2, 0.5% bovine serum albumin (BSA), where explosive conditions may develop.
    [Show full text]
  • Modelling the Affinity Maturation of B Lymphocytes in the Germinal Centre
    Modelling the Affinity Maturation of B Lymphocytes in the Germinal Centre By ADAM THOMAS REYNOLDS A thesis submitted to The University of Birmingham for the degree of MASTER OF PHILOSOPHY School of Biosciences The University of Birmingham June 2010 University of Birmingham Research Archive e-theses repository This unpublished thesis/dissertation is copyright of the author and/or third parties. The intellectual property rights of the author or third parties in respect of this work are as defined by The Copyright Designs and Patents Act 1988 or as modified by any successor legislation. Any use made of information contained in this thesis/dissertation must be in accordance with that legislation and must be properly acknowledged. Further distribution or reproduction in any format is prohibited without the permission of the copyright holder. To my Mum and Dad Acknowledgments I would like to thank all the people who have helped me directly and indirectly during this research project and helped me make this a memorable experience. I would like to thank Francesco Falciani, Kai Tollener, Mike Salmon, Micheal Hermann and Dov Stekel for technical support and guidance. I would also like to thank the BBSRC for providing funding for this thesis and thank Illogic for providing a licence to use the Rhapsody tool. I would also like to thank Antony Pemberton for help and support in the use of the Birmingham Biosciences High Performance Computer Cluster to perform the many computer simulations and to thank Ruth Harrison and the student support services who where invaluable in providing support and help with this thesis.
    [Show full text]
  • Antagonist Antibodies Against Various Forms of BAFF: Trimer, 60-Mer, and Membrane-Bound S
    Supplemental material to this article can be found at: http://jpet.aspetjournals.org/content/suppl/2016/07/19/jpet.116.236075.DC1 1521-0103/359/1/37–44$25.00 http://dx.doi.org/10.1124/jpet.116.236075 THE JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS J Pharmacol Exp Ther 359:37–44, October 2016 Copyright ª 2016 by The American Society for Pharmacology and Experimental Therapeutics Unexpected Potency Differences between B-Cell–Activating Factor (BAFF) Antagonist Antibodies against Various Forms of BAFF: Trimer, 60-Mer, and Membrane-Bound s Amy M. Nicoletti, Cynthia Hess Kenny, Ashraf M. Khalil, Qi Pan, Kerry L. M. Ralph, Julie Ritchie, Sathyadevi Venkataramani, David H. Presky, Scott M. DeWire, and Scott R. Brodeur Immune Modulation and Biotherapeutics Discovery, Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, Connecticut Received June 20, 2016; accepted July 18, 2016 Downloaded from ABSTRACT Therapeutic agents antagonizing B-cell–activating factor/B- human B-cell proliferation assay and in nuclear factor kB reporter lymphocyte stimulator (BAFF/BLyS) are currently in clinical assay systems in Chinese hamster ovary cells expressing BAFF development for autoimmune diseases; belimumab is the first receptors and transmembrane activator and calcium-modulator Food and Drug Administration–approved drug in more than and cyclophilin ligand interactor (TACI). In contrast to the mouse jpet.aspetjournals.org 50 years for the treatment of lupus. As a member of the tumor system, we find that BAFF trimer activates the human TACI necrosis factor superfamily, BAFF promotes B-cell survival and receptor. Further, we profiled the activities of two clinically ad- homeostasis and is overexpressed in patients with systemic vanced BAFF antagonist antibodies, belimumab and tabalumab.
    [Show full text]
  • TACI:Fc Scavenging B Cell Activating Factor (BAFF) Alleviates Ovalbumin-Induced Bronchial Asthma in Mice
    EXPERIMENTAL and MOLECULAR MEDICINE, Vol. 39, No. 3, 343-352, June 2007 TACI:Fc scavenging B cell activating factor (BAFF) alleviates ovalbumin-induced bronchial asthma in mice 1,2,3 2 Eun-Yi Moon and Sook-Kyung Ryu the percentage of non-lymphoid cells and no changes were detected in lymphoid cell population. 1 Department of Bioscience and Biotechnology Hypodiploid cell formation in BALF was decreased Sejong University by OVA-challenge but it was recovered by TACI:Fc Seoul 143-747, Korea treatment. Collectively, data suggest that asthmatic 2 Laboratory of Human Genomics symptom could be alleviated by scavenging BAFF Korea Research Institute of Bioscience and Biotechnology (KRIBB) and then BAFF could be a novel target for the Daejeon 305-806, Korea develpoment of anti-asthmatic agents. 3 Corresponding author: Tel, 82-2-3408-3768; Fax, 82-2-466-8768; E-mail, [email protected] Keywords: asthma; B-cell activating factor; ovalbu- and [email protected] min; transmembrane activator and CAML interactor protein Accepted 28 March 2007 Introduction Abbreviations: BAFF, B cell activating factor belonging to TNF- family; BALF, bronchoalveolar lavage fluid; OVA, ovalbumin; PAS, Mature B cell generation and maintenance are regu- periodic acid-Schiff; Prx, peroxiredoxin; TACI, transmembrane lated by B-cell activating factor (BAFF). BAFF is pro- activator and calcium modulator and cyclophilin ligand interactor duced by macrophages or dendritic cells upon stim- ulation with LPS or IFN- . BAFF belongs to the TNF family. Its biological role is mediated by the specific Abstract receptors, B-cell maturation antigen (BCMA), trans- membrane activator and calcium modulator and cy- Asthma was induced by the sensitization and chal- clophilin ligand interactor (TACI) and BAFF receptor, lenge with ovalbumin (OVA) in mice.
    [Show full text]
  • Does Recycling in Germinal Centers Exist?
    Does Recycling in Germinal Centers Exist? Michael Meyer-Hermann Institut f¨ur Theoretische Physik, TU Dresden, D-01062 Dresden, Germany E-Mail: [email protected] Abstract: A general criterion is formulated in order to decide if recycling of B-cells exists in GC reactions. The criterion is independent of the selection and affinity maturation process and based solely on total centroblast population arguments. An experimental test is proposed to verify whether the criterion is fulfilled. arXiv:physics/0102062v2 [physics.bio-ph] 6 Mar 2002 1 1 Introduction The affinity maturation process in germinal center (GC) reactions has been well charac- terized in the last decade. Despite a lot of progress concerning the morphology of GCs and the stages of the selection process, a fundamental question remains unsolved: Does recycling exist? Recycling means a back differentiation of antibody presenting centrocytes (which undergo the selection process and interact with antigen fragments or T-cells) to centroblasts (which do not present antibodies and therefore do not interact with antigen fragments but proliferate and mutate). The existence of recycling in the GC has important consequences for the structure of the affinity maturation process in GC reactions. The centroblasts proliferate and mutate with high rates in the environment of follicular dendritic cells. During the GC reaction they differentiate to antibody presenting centrocytes which may then be selected by inter- action with antigen fragments and T-cells. If the positively selected centrocytes recycle to (proliferating and mutating) centroblasts the antibody-optimization process in GCs may be compatible with random mutations of the centroblasts.
    [Show full text]
  • CD134 (OX40) Antibodies, Human for Research Use Only
    CD134 (OX40) antibodies, human For research use only One test corresponds to labeling of up to 107 cells in a total volume of 100 µL. Product Content Order no. CD134 (OX40)­VioBright FITC for 30 tests 130­109­664 CD134 (OX40)­VioBright FITC for 100 tests 130­109­605 CD134 (OX40)­PE for 30 tests 130­109­660 CD134 (OX40)­PE for 100 tests 130­109­601 CD134 (OX40)­APC for 30 tests 130­109­661 CD134 (OX40)­APC for 100 tests 130­109­602 CD134 (OX40)­PE­Vio770 for 30 tests 130­109­662 CD134 (OX40)­PE­Vio770 for 100 tests 130­109­603 CD134 (OX40)­APC­Vio770 for 30 tests 130­109­663 CD134 (OX40)­APC­Vio770 for 100 tests 130­109­604 CD134 (OX40)­Biotin for 30 tests 130­109­659 CD134 (OX40)­Biotin for 100 tests 130­109­600 Warnings Reagents contain sodium azide. Under acidic conditions sodium azide yields hydrazoic acid, which is extremely toxic. Azide compounds should be diluted with running water before discarding. These precautions are recommended to avoid deposits in plumbing where explosive conditions may develop. Technical data and background information Antigen CD134 (OX40) Clone REA621 Isotype recombinant human IgG1 Isotype control REA Control (S) antibodies Alternative names of antigen OX­40, OX40 Molecular mass of antigen [kDa] 27 Distribution of antigen B cells, endothelial cells, fibroblasts, lymphocytes, T cells Product format Reagents are supplied in buffer containing stabilizer and 0.05% sodium azide. Fixation Cells should be stained prior to fixation, if formaldehyde is used as a fixative. Storage Store protected from light at 2–8 °C.
    [Show full text]
  • Lymph Node Cytology
    Lymph node cytopathology : A practical approach to lymphoproliferative disorders • Koray Ceyhan, M.D • Department of Pathology • Faculty of Medicine • Ankara University • Ankara, Turkey Diagnostic use of FNA in lymph node pathologies • Well-established : • - metastatic malignancy, • - lymphoma recurrences • -some reactive or inflammatory disorders: Tuberculosis,sarcoidosis • Diagnostic sensitivity/accuracy : usually above 95% • Controversial: • primary lymphoma diagnosis • Diagnostic sensitivity varies from 12% to 96% Academic institutions: high level diagnostic accuracy Community practise the accuracy rate significantly low Multiparameter approach is critical for definitive lymphoma diagnosis • Cytomorphologic features alone are not sufficient for the diagnosis of primary lymphoma • Immunophenotyping with flow cytometry and/or immunocytochemistry is mandatory • In selected cases molecular/cytogenetic analyses are required for definitive lymphoma classification Lymph node pathologies • 1-Reactive lymphoid hyperplasia/inflammatory disorders • 2-Lymphoid malignancies • 3-Metastatic tumors 1 3 2 Common problems in lymph node cytology • Reactive lymphoid hyperplasia vs lymphoma • Primary lymphoma diagnosis(lymphoma subtyping) • Predicting primary site of metastatic tumor • Nonlymphoid tumors mimicking lymphoid malignancies • Correct diagnosis of specific benign lymphoid lesions Problem 1: Reactive vs lymphoma Case 19- years-old boy Multiple bilateral cervical LAPs for 4 weeks FNA from the largest cervical lymph node measuring 15X13 mm No
    [Show full text]
  • The Thrombopoietin Receptor : Revisiting the Master Regulator of Platelet Production
    This is a repository copy of The thrombopoietin receptor : revisiting the master regulator of platelet production. White Rose Research Online URL for this paper: https://eprints.whiterose.ac.uk/175234/ Version: Published Version Article: Hitchcock, Ian S orcid.org/0000-0001-7170-6703, Hafer, Maximillian, Sangkhae, Veena et al. (1 more author) (2021) The thrombopoietin receptor : revisiting the master regulator of platelet production. Platelets. pp. 1-9. ISSN 0953-7104 https://doi.org/10.1080/09537104.2021.1925102 Reuse This article is distributed under the terms of the Creative Commons Attribution (CC BY) licence. This licence allows you to distribute, remix, tweak, and build upon the work, even commercially, as long as you credit the authors for the original work. More information and the full terms of the licence here: https://creativecommons.org/licenses/ Takedown If you consider content in White Rose Research Online to be in breach of UK law, please notify us by emailing [email protected] including the URL of the record and the reason for the withdrawal request. [email protected] https://eprints.whiterose.ac.uk/ Platelets ISSN: (Print) (Online) Journal homepage: https://www.tandfonline.com/loi/iplt20 The thrombopoietin receptor: revisiting the master regulator of platelet production Ian S. Hitchcock, Maximillian Hafer, Veena Sangkhae & Julie A. Tucker To cite this article: Ian S. Hitchcock, Maximillian Hafer, Veena Sangkhae & Julie A. Tucker (2021): The thrombopoietin receptor: revisiting the master regulator of platelet production, Platelets, DOI: 10.1080/09537104.2021.1925102 To link to this article: https://doi.org/10.1080/09537104.2021.1925102 © 2021 The Author(s).
    [Show full text]
  • Role of ADAM10 and ADAM17 in Regulating CD137 Function
    International Journal of Molecular Sciences Article Role of ADAM10 and ADAM17 in Regulating CD137 Function Jana Seidel 1, Sinje Leitzke 1, Björn Ahrens 1, Maria Sperrhacke 1, Sucharit Bhakdi 2 and Karina Reiss 1,* 1 Department of Dermatology, University of Kiel, 24105 Kiel, Germany; [email protected] (J.S.); [email protected] (S.L.); [email protected] (B.A.); [email protected] (M.S.) 2 Independent Researcher, 24105 Kiel, Germany; [email protected] * Correspondence: [email protected] Abstract: Human CD137 (4-1BB), a member of the TNF receptor family, and its ligand CD137L (4-1BBL), are expressed on immune cells and tumor cells. CD137/CD137L interaction mediates bidirectional cellular responses of potential relevance in inflammatory diseases, autoimmunity and oncology. A soluble form of CD137 exists, elevated levels of which have been reported in patients with rheumatoid arthritis and various malignancies. Soluble CD137 (sCD137) is considered to represent a splice variant of CD137. In this report, however, evidence is presented that A Disintegrin and Metalloproteinase (ADAM)10 and potentially also ADAM17 are centrally involved in its generation. Release of sCD137 by transfected cell lines and primary T cells was uniformly inhibitable by ADAM10 inhibition. The shedding function of ADAM10 can be blocked through inhibition of its interaction with surface exposed phosphatidylserine (PS), and this effectively inhibited sCD137 generation. The phospholipid scramblase Anoctamin-6 (ANO6) traffics PS to the outer membrane and thus modifies ADAM10 function. Overexpression of ANO6 increased stimulated shedding, and hyperactive ANO6 led to maximal constitutive shedding of CD137.
    [Show full text]
  • Successful Treatment of CD30+Lymphomatoid Papulosis
    ooggeenneessii iinn ss && rrcc aa MM CC uu tt ff aa Journal ofJournal of oo gg ll ee ee aa aa nn nn nn nn ee ee rr rr ss ss uu uu ii ii Watabe et al., J Carcinog Mutagen 2014, 5:3 ss ss oo oo JJ JJ ISSN: 2157-2518 CarCarcinogenesiscinogenesis & Mutagenesis DOI: 10.4172/2157-2518.1000174 Case Report Open Access Successful Treatment of CD30+Lymphomatoid Papulosis using a 308-nm Excimer Light Akiko Watabe, Taku Fujimura*, Sadanori Furudate and Setsuya Aiba Department of Dermatology, Tohoku University Graduate School of Medicine, Sendai, Japan *Corresponding author: Taku Fujimura, Department of Dermatology, Tohoku University Graduate School of Medicine, Seiryo-machi 1-1, Aoba-ku, Sendai, 980-8574, Japan, Tel:+81 (22) 717-7271; Fax: +81 (22) 717-7361; E-mail: [email protected] Received date: Mar 11, 2014, Accepted date: May 03, 2014, Published date: May 07, 2014 Copyright: © 2013 Watabe A, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited Abstract We describe a 61-year-old Japanese patient with Lymphomatoid papulosis (LYP) successfully archived complete remission, using a 308-nm Excimer light. Interestingly, immunohistochemical staining revealed that CD30+ anaplastic tumor cells were surrounded by CD163+ macrophages and CCL18 producing cells, both of which were reported to correlate with the prognosis of CTCL. Our present study sheds light on the possible pathogenesis of LYP and the possibility of a 308-nm Excimer light phototherapy for LYP.
    [Show full text]
  • FS222, a CD137/PD-L1 Tetravalent Bispecific Antibody, Exhibits Low Toxicity and Antitumor Activity in Colorectal Cancer Models
    Published OnlineFirst April 28, 2020; DOI: 10.1158/1078-0432.CCR-19-2958 CLINICAL CANCER RESEARCH | TRANSLATIONAL CANCER MECHANISMS AND THERAPY FS222, a CD137/PD-L1 Tetravalent Bispecific Antibody, Exhibits Low Toxicity and Antitumor Activity in Colorectal Cancer Models A C Matthew A. Lakins, Alexander Koers, Raffaella Giambalvo, Jose Munoz-Olaya, Robert Hughes, Emma Goodman, Sylwia Marshall, Francisca Wollerton, Sarah Batey, Daniel Gliddon, Mihriban Tuna, and Neil Brewis ABSTRACT ◥ Purpose: With the increased prevalence in checkpoint therapy Results: We demonstrated simultaneous binding of CD137 þ resistance, there remains a significant unmet need for additional andPD-L1andshowedpotentT-cell activation across CD8 therapies for patients with relapsing or refractory cancer. We have T-cell activation assays in a PD-L1–dependent manner with a developed FS222, a bispecific tetravalent antibody targeting CD137 CD137/PD-L1 bispecific antibody, FS222. FS222 also activated and PD-L1, to induce T-cell activation to eradicate tumors without T cells in a human primary mixed lymphocyte reaction assay, with the current toxicity and efficacy limitations seen in the clinic. greater potency than the monospecific mAb combination. FS222 Experimental Design: A bispecific antibody (FS222) was devel- showed no signs of liver toxicity up to 30 mg/kg in a non-human oped by engineering CD137 antigen–binding sites into the Fc region primate dose-range finding study. A surrogate molecule caused of a PD-L1 IgG1 mAb. T-cell activation by FS222 was investigated significant tumor growth inhibition and survival benefit, concom- þ using multiple in vitro assays. The antitumor efficacy, survival itant with CD8 T-cell activation, in CT26 and MC38 syngeneic benefit, pharmacodynamics, and liver pharmacology of a murine mouse tumor models.
    [Show full text]
  • CD27 APC Catalog Number(S): 9017-0279-025 (25 Tests), 9017-0279-120 (120 Tests)
    Page 1 of 2 CD27 APC Catalog Number(s): 9017-0279-025 (25 tests), 9017-0279-120 (120 tests) Fluorescence profiles of normal human peripheral blood lymphocytes unstained (blue histogram) or stained with CD27 APC (purple histogram). Product Information Contents: CD27 APC Storage Conditions: Store at 2-8°C. Catalog Number(s): 9017-0279-025 (25 tests), Do not freeze. 9017-0279-120 (120 tests) Light-sensitive material. Clone: O323 Caution, contains Azide Concentration: 5 uL (0.25 ug)/test (a test is Manufacturer: eBioscience, Inc., 10255 Science defined as the amount that will stain Center Drive, San Diego, CA 92121, USA 1 x 10e6 cells in 100 uL) Authorized Representative: Bender Host/Isotype: Mouse IgG1, kappa MedSystems GmbH, an eBioscience Company HLDA Workshop: IV Campus Vienna Biocenter 2 A-1030 Vienna Formulation: Aqueous buffer, 0.09% sodium Austria azide, may contain carrier protein/stabilizer. Intended Use Description The O323 fluorochrome-conjugated monoclonal The O323 monoclonal antibody reacts with human antibody reacts with the human CD27 antigen. CD27 CD27, a lymphocyte-specific member of the TNFR can be detected in human biological samples using superfamily. CD27 is expressed by a subset of thymocytes immunological techniques. and virtually all mature T cells and is upregulated upon Principles of the Test T-cell stimulation. CD27 binds to CD70, and through Flow cytometry is a useful tool for simultaneously this interaction, plays an important role in T cell-B cell measuring multiple physical properties of individual interaction. particles (such as cells). Cells pass single-file through a Specimen Collection and Storage Instructions laser beam.
    [Show full text]